Aqueous olanexidine versus aqueous povidone-iodine for surgical skin antisepsis on the incidence of surgical site infections after clean-contaminated surgery: a multicentre, prospective, blinded-endpoint, randomised controlled trial - 22/10/20
, Masashi Takeuchi, MD a, †, Hirofumi Kawakubo, MD a, Masahiro Shinoda, MD a, Koji Okabayashi, MD a, Koki Hayashi, MD a, Yasuhito Sekimoto, MD c, Yusuke Maeda, MD d, Takayuki Kondo, MD e, Yasunori Sato, PhD b, Yuko Kitagawa, MD aSummary |
Background |
Surgical site infection (SSI) is the most common problem after surgery. Although several guidelines have indicated the efficacy of antiseptics, such as chlorhexidine-alcohol and povidone-iodine, in reducing SSI rate, the optimal recommendation is still not established. Olanexidine might have higher bactericidal activity than other antiseptic agents. However, no randomised study has evaluated the efficacy and safety of olanexidine over conventional antiseptics. We compared the effect of aqueous olanexidine and aqueous povidone-iodine on the incidence of SSI following clean-contaminated surgery.
Methods |
This was a multicentre, prospective, randomised, blinded-endpoint superiority trial for surgical skin antisepsis in clean-contaminated gastrointestinal and hepatobiliary pancreatic surgeries in four Japanese hospitals. Patients aged 20 years or older who underwent elective clean-contaminated wound surgery were randomly assigned in a 1:1 replacement ratio using a computer-generated block randomisation. Patients were randomly assigned to surgical skin antisepsis with an aqueous formulation of 1·5% olanexidine or surgical skin antisepsis with an aqueous formulation of 10% povidone-iodine before surgery. We used olanexidine in a ready-to-use applicator, and povidone-iodine was administered by a brush or by compression using pliers. Both antiseptics were applied from the papilla with a cranial limit and to the upper thigh with a caudal limit. The antiseptics were allowed to dry for 3 min, and then surgery started. Participants, some investigators, and data analysts were masked to treatment allocation. Participant enrolment was done by non-masked investigators. The primary outcome was 30-day SSI assessed in the intention-to-treat population. The surgical wound site of each participant was observed daily. After discharge, participants underwent at least one outpatient visit within 30 days after surgery. This trial is registered with University hospital Medical Information Network, 000031560.
Findings |
Between June 10, 2018, and April 18, 2019, 883 patients were assessed for eligibility. 587 patients were eligible and 294 received olanexidine and 293 received aqueous povidone-iodine before surgery. 30-day SSI occurred in 19 (7%) patients in the olanexidine group and 39 patients (13%) patients in the povidone-iodine group (adjusted risk difference −0·069; 90% CI −0·109 to −0·029; adjusted risk ratio [RR] 0·48, 90% CI 0·30 to 0·74; p=0·002). Five patients (2%) in the olanexidine group and five (2%) in the povidone-iodine group developed adverse skin reactions (adjusted RR 0·99, 95% CI 0·29 to 3·40; p=1·00).
Interpretation |
Olanexidine significantly reduced the occurrence of overall SSI and superficial incisional SSI compared with aqueous povidone-iodine in clean-contaminated surgery. Our results indicate that olanexidine might have a role to prevent SSI in patients who undergo clean-contaminated surgeries.
Funding |
Keio University and Ohyama Health Foundation.
Le texte complet de cet article est disponible en PDF.Plan
Vol 20 - N° 11
P. 1281-1289 - novembre 2020 Retour au numéro
Article précédent
- COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study
- Reina S Sikkema, Suzan D Pas, David F Nieuwenhuijse, Áine O’Toole, Jaco Verweij, Anne van der Linden, Irina Chestakova, Claudia Schapendonk, Mark Pronk, Pascal Lexmond, Theo Bestebroer, Ronald J Overmars, Stefan van Nieuwkoop, Wouter van den Bijllaardt, Robbert G Bentvelsen, Miranda M L van Rijen, Anton G M Buiting, Anne J G van Oudheusden, Bram M Diederen, Anneke M C Bergmans, Annemiek van der Eijk, Richard Molenkamp, Andrew Rambaut, Aura Timen, Jan A J W Kluytmans, Bas B Oude Munnink, Marjolein F Q Kluytmans van den Bergh, Marion P G Koopmans
- Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study
- Maja Jahnmatz, Laura Richert, Nabil al-Tawil, Jann Storsaeter, Céline Colin, Claire Bauduin, Marcel Thalen, Ken Solovay, Keith Rubin, Nathalie Mielcarek, Rigmor Thorstensson, Camille Locht, BPZE1 study team, Lena Dager, Nina Ekholm, Margareta Gustafsson, Åsa Linde, Cecilia Lång, Maria Nastase, Inga-Lill Reinholdsson, Erla Sigurdardottir, Anneli Wahlberg, Izabella Zarea, Teodora Aktas, Ingrid Andersson, Eva Hanson Pihlainen, Margaretha Ljungman, Maj Ringman, Teghesti Tecleab, Lena Wehlin, Florence Allais, Alex Assuied, Geneviève Chêne, Camille Gilbert, Delphine Jean, Fabien Le Marec, Laetitia Moinot, Philippe Reboud, Emilie Rousseau, Céline Roy, Christine Schwimmer, Ludivine Taïeb, Cédrick Wallet, Gabrielle Derocle, Sonia Gueguen, Claire Lévy-Marchal, Hélène Esperou, Anne-Sophie Debrie, Dominique Raze, Loïc Coutte, Alpha Diallo, Noémie Mercier
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?